LLY ▲ +0.3% - Eli Lilly and Company
$LLY - Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
29-SEP-2026 03:00 AM ET
Share this post
More filings for $LLY
LLY ▲ +0.6% - Eli Lilly and CompanySep 28, 2026LLY ▲ +0.1% - Eli Lilly and CompanySep 25, 2026LLY ▲ +2.3% - Eli Lilly and CompanySep 24, 2026LLY ▼ -0.4% - Eli Lilly and CompanySep 24, 2026LLY ▼ -0.4% - Eli Lilly and CompanySep 24, 2026LLY ▲ +1.2% - Eli Lilly and CompanySep 21, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment
